REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses

Wait 5 sec.

SAN DIEGO, Aug. 19, 2026 /PRNewswire/ -- Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026, inclusive (the...